Achieve Life Sciences Completes U.S. Manufacturing Transfer Amid FDA Review — Achieve Life Sciences, Inc.

Event summary

Achieve Life Sciences completed technology transfer of cytisinicline manufacturing to Adare Pharma Solutions' U.S. facility in Vandalia, Ohio.
First engineering batch of cytisinicline produced at Adare, a critical step before commercial-scale production.
FDA issued an Official Action Indicated (OAI) classification for Achieve's third-party manufacturing facility, unrelated to cytisinicline.
Company expects FDA Complete Response Letter by June 20, 2026, and plans to resubmit NDA in Q4 2026.
Cytisinicline commercial launch still targeted for first half of 2027 if approved.

The big picture

Achieve's manufacturing transfer to Adare reflects a broader industry shift toward domestic production amid rising geopolitical and regulatory pressures. The move also underscores the strategic importance of supply chain redundancy as the FDA tightens scrutiny on imported pharmaceuticals. With a $25 billion U.S. smoking cessation market and no FDA-approved treatments for vaping cessation, cytisinicline's approval could position Achieve as a key player in nicotine dependence treatment.

What we're watching

Regulatory Headwinds: How the FDA's OAI classification will impact the resubmission timeline and approval prospects for cytisinicline.
Supply Chain Strategy: Whether Achieve's U.S.-based manufacturing partnership with Adare can mitigate tariff risks and ensure uninterrupted supply.
Commercial Readiness: The pace at which Achieve can scale production and prepare for a potential 2027 launch amid ongoing regulatory scrutiny.